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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: :    The peroxisome proliferator-activated receptors (PPARs) are ligand-activated
transcription factors and members of the nuclear receptor superfamily. The PPAR family consists
of three members: PPARa, PPARg, and PPARd. PPARd controls the transcription of genes
involved in multiple physiological pathways, including cellular differentiation, lipid metabolism and
energy homeostasis. The receptor is expressed almost ubiquitously, with high expression in liver
and skeletal muscle. Although the physiological ligands of PPARd remain undefined, a number of
high affinity synthetic ligands have been developed for the receptor as a therapeutic target for
type 2 diabetes mellitus, dyslipidemia and the metabolic syndrome.
M Me et th ho od ds s: : In this study, the metabolic role of PPARd activation has been investigated in liver,
skeletal muscle, blood serum and white adipose tissue from ob/ob mice using a high affinity
synthetic ligand and contrasted with PPARg activation. To maximize the analytical coverage of the
metabolome, 1H-nuclear magnetic resonance (1H-NMR) spectroscopy, gas chromatography-mass
spectrometry (GC-MS) and ultra performance liquid chromatography-mass spectrometry
(UPLC-MS) were used to examine metabolites from tissue extracts.
R Re es su ul lt ts s: : Analysis by multivariate statistics demonstrated that PPARd activation profoundly
affected glycolysis, gluconeogenesis, the TCA cycle and linoleic acid and a-linolenic acid essential
fatty acid pathways.
C Co on nc cl lu us si io on ns s: : Although activation of both PPARd and PPARg lead to increased insulin sensitivity
and glucose tolerance, PPARd activation was functionally distinct from PPARg activation, and was
characterized by increased hepatic and peripheral fatty acid oxidative metabolism, demonstrating
the distinctive catabolic role of this receptor compared with PPARg.
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The peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors that control the
expression of genes involved in organogenesis, inflammation,
cell differentiation, proliferation, and lipid and carbohydrate
metabolism [1,2]. A number of synthetic compounds used to
treat type 2 diabetes and dyslipidemia are PPAR ligands.
Upon binding their ligands, PPARs heterodimerize with the
9-cis-retinoic acid receptor and then bind to target gene
peroxisome proliferator response elements, a direct repeat of
the sequence AGGTCA separated by one nucleotide [3].
Three distinct subtypes of PPARs have been identified,
PPARα, PPARδ and PPARγ, each demonstrating its own
specific tissue distribution and ligand preference [4]. PPARδ
is expressed almost ubiquitously, though some tissues
express higher concentrations of the mRNA, including the
brain, adipose tissue, skin, liver and skeletal muscle [5,6]. In
addition, PPARδ protein expression has recently been shown
to be high in liver, colon, small intestine and keratinocytes
[7]. The receptor is activated by several 14- to 18-carbon-
containing polyunsaturated fatty acids, including eicosanoids
such as prostaglandin A1, iloprost and carbaprostacyclin [8].
In comparison to PPARα and PPARγ, PPARδ has been the
focus of far less research, despite its potential clinical role.
This is in part because only relatively recently have high
affinity synthetic PPARδ ligands been developed that may be
used for the treatment of the metabolic syndrome. Insulin-
resistant obese rhesus monkeys treated with the selective
PPARδ agonist GW501516 demonstrated significant increases
in high-density lipoprotein (HDL) cholesterol with conco-
mitant decreases in triglycerides and low-density lipoprotein
cholesterol [9]. PPARδ activation reduced adiposity by
decreasing intracellular triglyceride accumulation in mouse
brown adipose tissue and liver and also enhanced β-
oxidation in 3T3-L1 mouse preadipocytes [10]. PPARδ
mRNA is expressed at 10 and 50 times the concentrations of
PPARα and PPARγ mRNA [11], respectively, in skeletal
muscle and administration of PPARδ agonists to rodents
results in an increase in expression of genes involved in fatty
acid oxidation, mitochondrial respiration, oxidative metabo-
lism and slow twitch contractile apparatus, decreasing muscle
fatigability [12]. However, the ubiquitous expression of PPARδ
may result in diverse and unwanted side effects upon
activation of this receptor. The nuclear receptor has been
implicated in the acceleration of intestinal adenoma growth
and increased growth in breast and prostate cancer cell lines,
but conversely it also attenuates colon cancer [13-15]. The role
of PPARδ in development and carcinogenesis is complex and
has been previously reviewed [16]. PPARδ activation has also
been implicated as a cause of muscle atrophy [17].
It is hypothesized that the insulin sensitizing effects of
PPARδ activation are brought about by changes in systemic
metabolism. Given that triglyceride in liver contributes to
insulin resistance, it has been suggested that increased
triglyceride oxidation in the liver, caused by PPARδ
activation, may contribute to this improvement [18]. There-
fore, this study aims to use metabolomics to examine the
changes that occur in hepatic metabolism following PPARδ
activation and the impact detected systemically through
metabolite changes in blood serum and skeletal muscle in
the ob/ob mouse. The ob/ob mouse model of insulin resis-
tance is robust, well characterized and used extensively to
study type 2 diabetes and its therapies; however, it is worthy
of note that it is a monogenic paradigm of leptin deletion,
whereas type 2 diabetes mellitus is a polygenic disorder. This
study has used metabolomics in conjunction with traditional
clinical chemistry end points to investigate the effects of a
PPARδ agonist in contrast to a PPARγ agonist on liver, skeletal
muscle, serum and white adipose tissue in the ob/ob mouse.
M Me et th ho od ds s
C Cl li in ni ic ca al l   c ch he em mi is st tr ry y
All clinical chemistry measurements were performed using
an Olympus AU 400e Analyzer [19]. Insulin measurements
were performed by ELISA (Millipore Mouse Insulin ELISA
kit, Billerica, MA, USA).
O Or ra al l   g gl lu uc co os se e   t to ol le er ra an nc ce e   t te es st t
Animals were fasted overnight prior to the oral glucose
tolerance test (day 12). Glucose concentrations were measured
using the FreeStyle Blood Glucose Monitoring System
(TheraSense, Fleet, UK). Animals were dosed orally with
1 g/kg glucose. Baseline fasted glucose values were collected
at the 0 minute time point. Glucose concentrations were
collected at 15, 30, 60 and 90 minute intervals. All time
points were collected via tail snips.
T Ti is ss su ue e   c co ol ll le ec ct ti io on n   a an nd d   e ex xt tr ra ac ct ti io on n
All animal studies were performed within the relevant local
legislation. Two-month-old male ob/ob mice (Jackson Labs,
Bar Harbor, ME, USA), with no significant variation in
initial body weight (data not shown), were fed standard
laboratory chow ad libitum under controlled temperature
and lighting (20-22°C, 12-h light-dark cycle). The ob/ob
mice were assigned to three groups of eight and dosed orally
daily at 8 am with 0.5% hydroxypropylmethylcellulose/0.1%
Tween80 vehicle control, a PPARδ agonist, GW610742
(30 mg/kg), and a PPARγ agonist, GW347845 (5 mg/kg).
Injection volume was adjusted daily according to body
weight at 10 ml/kg. Serum was collected via cardiac stick
under isoflourane anesthesia at completion of the study (day
15). Skeletal muscle (gastrocnemius), liver and white adipose
tissue were rapidly dissected (<60 s post mortem), snap
frozen in liquid nitrogen and stored at -80°C until extraction.
Metabolites were extracted from tissues using a modified
Bligh and Dyer method [20]. Frozen tissue (approximately
100 mg for nuclear magnetic resonance (NMR) and approxi-
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(GC-MS) analysis) was pulverized with liquid nitrogen.
Methanol-chloroform (600 µl; 2:1 v/v) was added to the
pulverized tissue or serum (50 µl) and the samples were
sonicated for 15 minutes. Chloroform-water (1:1) was then
added (200 µl of each). Samples were centrifuged (16,100 g,
20 minutes) and the two phases were separated; the organic
phase was dried in a fume hood; the aqueous phase was
dried in an evacuated centrifuge.
1 1H H- -N NM MR R   s sp pe ec ct tr ro os sc co op py y
Dried extracts were dissolved in 600 µl of D2O and buffered in
0.24 M sodium phosphate (pH 7.4) containing 1 mM sodium-
3-(trimethylsilyl)-2,2,3,3-tetradeuteriopropionate (TSP; Cam-
bridge Isotope Laboratories, Andover, MA, USA) and
0.02 M sodium azide. Samples were analyzed using a DRX
Avance II+ spectrometer interfaced to a 5-mm TXI ATMA
probe (Bruker BioSpin GmbH, Rheinstetten, Germany) at a
proton frequency of 500.13 MHz. A presaturation pulse
sequence for water suppression based on a one-dimensional
nuclear Overhauser effect spectroscopy pulse sequence was
used to saturate the residual water proton signal (relaxation
delay = 2 s, t1 = 4 µs, mixing time = 50 ms, presaturation
applied during the relaxation time and mixing time). We
collected 128 transients into 64k data points over a spectral
width of 8,000 Hz at 300K. NMR spectra were processed in
ACD 1D NMR Manager (version 8; Advanced Chemistry
Development Inc., Toronto, Canada), multiplied by an
exponential weighting function of 1 Hz, Fourier transformed,
phased, baseline corrected and referenced to TSP at 0.0
ppm. The NMR spectra were integrated using 0.04-ppm
integral regions between 0.2 and 9.56 ppm (excluding water
resonance between 4.20 and 5.08 ppm). Spectra were
normalized to total integrated area to account for differences
in concentration between samples and assigned by
comparison with previous literature.
G Ga as s   c ch hr ro om ma at to og gr ra ap ph hy y- -m ma as ss s   s sp pe ec ct tr ro om me et tr ry y   a an na al ly ys si is s
Dried aqueous phase samples were derivatized by adding
30 µl of methoxyamine hydrochloride solution (20 mg/ml in
pyridine; Sigma-Aldrich Ltd, Dorset, UK), vortex mixed for
1 minute then incubated at 25°C for 17 h. Samples were
silylated with 30 µL of N-methyl-N-trimethylsilyltrifluoro-
acetamide (Macherey-Nagel, Duren, Germany) for 1 h at
25°C [21]. The samples were then diluted by addition of
200 µL of analytical grade hexane prior to GC-MS analysis.
Acid-catalyzed esterification was used to derivatize the
organic phase samples. Chloroform-methanol (1:1, 0.25 ml)
and BF3-methanol (10%; 0.125 ml) was added to the organic
phase and incubated at 90°C for 90 minutes. Water (0.15 ml;
mQ) and hexane (0.3 ml) were added and the samples vortex
mixed for 1 minute and left to form a bilayer. The aqueous
phase was discarded and the organic layer evaporated to
dryness prior to reconstitution in analytical grade hexane
(200 µl) before GC-MS analysis.
All GC-MS analyses were made using a Trace GC Ultra
coupled to a DSQ single-quadrupole mass spectrometer
(ThermoScientific, Hemel Hempstead, UK). Derivatized
aqueous samples were injected splitless onto a 30 m ×
0.25 mm 5% phenylpolysilphenylene-siloxane column with a
0.25 µm ZB-5ms stationary phase (Phenomenex, Maccles-
field, Cheshire, UK). The injector temperature was 230°C
and helium carrier gas was used at a flow rate of
1.2 ml/minute. The initial column temperature of 70°C was
increased by 5°C/minute to 230°C and then increased at a
rate of 20°C/minute to 310°C (transfer line temperature =
250°C; ion source = 250°C; electron ionization = 70 eV).
The detector was turned on after 240 s and full-scan spectra
were collected using three scans/s over a range of 50 to
650 m/z.
The derivatized organic samples were injected with a split
ratio of 8 onto a 30 m × 0.25 mm 70% cyanopropyl poly-
silphenylene-siloxane 0.25 µm TR-FAME stationary phase
column (ThermoScientific). The injector temperature was
set to 230°C and helium carrier gas was at a flow rate of
1.2 ml/minute. The column temperature was 60°C for
2 minutes, increased by 15°C/minute to 150°C and then
increased at a rate of 4°C/minute to 230°C (transfer line =
240°C; ion source = 250°C; electron ionization = 70 eV). The
detector was set as above for the ZB-5ms column.
GC-MS chromatograms were processed using Xcaliber
(version 2.0; ThermoScientific). Each individual peak was
integrated and then normalized. Overlapping peaks were
separated using traces of single ions. Peak assignment was
based on mass fragmentation patterns matched to the
National Institute of Standards and Technology library and
to previously reported literature. Identification of metabo-
lites from organic phase GC-MS analysis was supported by
comparison with a FAME standard mix (Supelco 37
Component FAME Mix; Sigma Aldrich).
U Ul lt tr ra a   p pe er rf fo or rm ma an nc ce e   l li iq qu ui id d   c ch hr ro om ma at to og gr ra ap ph hy y- -m ma as ss s   s sp pe ec ct tr ro om me et tr ry y
a an na al ly ys si is s
Chromatography was performed using an ACQUITY UPLC
System (Waters Corporation, Elstree, Hertfordshire, UK)
equipped with an Acquity UPLC 1.7 µm bridged ethyl hybrid
C8 column (2.1 × 100 mm; Waters Corporation) that was
kept at 65°C and coupled to a Micromass QTof-Micro™ with
a Z-spray™ electrospray source. The electrospray source was
operated in positive ion mode with the source temperature
set at 100°C and a cone gas flow of 50 L/h. The desolvation
gas temperature was 300°C and the nebuliser gas flow rate
was set at 600 L/h. The capillary voltage was 3 kV and the
cone voltage was 40 V. The binary solvent system used was
solvent A (HPLC grade water, 1% 1 M ammonium acetate
(NH4Ac), 0.1% formic acid) and solvent B (analytical grade
acetonitrile/isopropanol 5:2, 1% 1 M NH4Ac, 0.1% formic
acid) [22]. The temperature of the sample organizer was set
at 4°C. Mass spectrometric data were collected in full scan
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scan duration of 0.5 s and an interscan delay of 0.1 s.
The organic phase of liver and serum were reconstituted in
methanol-chloroform (2:1, 500 µl). This was further diluted
7.5-fold and 4-fold, respectively, for the different tissues
prior to injection onto the C8 column due to variation
between lipid concentrations in the tissues (5 µl and 10 µl,
respectively). For both the liver and serum samples the
column mobile phase was held at 70% solvent B for
0.5 minutes followed by an increase from 70 to 100% solvent
B over 0.5 to 6.5 minutes. The mobile phase was then held at
100% solvent B for 3.5 minutes. Between 10 and
10.25 minutes the mobile phase was returned to 70% solvent
B held for 3.75 minutes to re-equilibrate the column. The
total ultra performance liquid chromatography (UPLC) cycle
was 14 minutes. The eluent flow rate was 600 µl/minute.
Tandem mass spectrometry (MS/MS) was used for the
identification of selected lipids. MS/MS runs were per-
formed using ESI+ mode and collision energies of 16, 18, 20,
25, 28 V and a mass range of 80 to 1,100 m/z. Other
conditions were as described above.
Data were processed using Micromass Markerlynx
Applications Manager (Waters Corporation). Each peak was
detected, noise-reduced and integrated. The ion-intensities
for each peak were detected and normalized. Lipids were
identified using the tandem mass spectrometry data.
M Mu ul lt ti iv va ar ri ia at te e   a an na al ly ys si is s
Multivariate data analysis was performed using SIMCA-P+
11.0 (Umetrics AB, Umeå, Sweden). NMR data sets were
mean-centered and Pareto-scaled prior to analysis. Pareto
scaling involves weighting each of the variables by the square
root of that variable’s variance, minimizing the impact of
noise and increasing the importance of low-concentration
metabolites in the subsequent analysis. GC-MS data sets were
unit variance scaled. Unit variance scaling weights each of the
variables by the variable’s group standard deviation and
therefore does not bias models towards large concentration
metabolites. Data sets were analyzed using principal
components analysis (PCA) and partial least squares-discri-
minate analysis (PLS-DA). Metabolite changes responsible
for clustering or regression trends within the pattern recog-
nition models were identified by interrogating the corres-
ponding loadings plot. Metabolites identified in the Variable
Importance Parameter (VIP)/coefficients plots were deemed
to have changed globally if they contributed to separation in
the models with a confidence limit of 95% or greater.
R Re es su ul lt ts s
C Cl li in ni ic ca al l   c ch he em mi is st tr ry y
The concentrations of both insulin and glucose were found
to be significantly decreased in both PPARδ and PPARγ
agonist treated serum, indicating that the insulin resistant
status of the ob/ob mice is improved by PPARδ and  γ
activation. This was also confirmed by the oral glucose
tolerance test. The concentrations of β-hydroxybutyrate,
total cholesterol and HDL cholesterol were increased in the
serum of PPARδ agonist treated mice, while non-esterified
fatty acids were decreased in concentration. While, serum
triglyceride concentrations were increased in PPARδ agonist
treated mice, this class of compounds decreased in PPARγ
agonist treated mice (Figure 1).
M Me et ta ab bo ol lo om mi ic cs s
1H-NMR spectroscopy and GC-MS analysis, combined with
multivariate pattern recognition, were used to profile
metabolism within the liver, serum and skeletal muscle of
ob/ob mice treated with a PPARδ agonist and a PPARγ
agonist. The different analytical techniques had varying
sensitivities. High resolution 1H-NMR spectroscopy detected
20 to 25 metabolites in both liver and skeletal muscle.
GC-MS detected 100 to 150 defined peaks from aqueous
phase samples and 30 to 40 defined peaks from organic
phase samples. Matching the mass spectra detected with
those held in the National Institute of Standards library
identified 40 to 60% metabolites for aqueous extracts and
approximately 70% for lipids.
Phospholipid targeted UPLC-MS detected 100 to 150 unique
metabolite species in positive mode. Identification of
metabolite species was performed using MS/MS. Phospha-
tidylcholines were identified using the phosphocholine head
group ion (184 m/z).
To assess metabolic changes in the dataset, a common
processing strategy was adopted throughout the analysis. To
investigate metabolite perturbations common to PPARδ and
PPARγ activation, PCA and PLS-DA models were built for
the individual tissues treating the δ and γ agonists as part of
a common group. Although the groups were shown to co-
cluster and separate from the control group in this
supervised analysis, the majority of the Q2 values (testing
model statistical robustness) were low, despite the δ and γ
agonist treatment groups separating along the same scores
plot axis. While similar changes were detected in the
concentration of a large number of metabolites for both
treatments, these occurred with different magnitudes
(Figure 2). Activation of PPARδ in the liver and skeletal
muscle caused a greater magnitude of changes compared to
activation of PPARγ. These findings correspond to known
tissue distribution of the PPAR subtypes and that the two
receptors share a number of common metabolic effects.
Visual inspection of the 1H-NMR spectra and GC-MS
chromatograms indicated differences between the control
and treated groups. PCA and PLS-DA models were built for
the individual tissues comparing the control group with the
PPARδ agonist treated group and the control group with the
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fied in the VIP/coefficients plots as significantly contributing
to separation in the models were then considered to have
changed globally. Metabolite changes were then compared
between agonists (Additional files 1 and 2). The metabolite
changes in the individual tissues are considered below.
Liver
Metabolite changes unique to PPARδ activation
While only a decrease in the concentration of the ketogenic
amino acid lysine distinguished the animals treated with the
PPARδ agonist from the other groups for aqueous soluble
metabolites, this group was more readily distinguished by
lipid metabolites. The PPARδ agonist produced an increase
in the -CH3 and -(CH2)n lipid moieties, detected by 1H-NMR
spectroscopy. A decrease was detected in the concentrations
of 8,11-eicosadienoic acid, cis-10-heptadecanoic acid,
myristic acid, myristoleic acid, oleic acid, palmitic acid,
pentadecanoic acid and trans-11-eicosenoic acid. The
essential fatty acid pathways were also targeted with
increases in arachidonic acid, dihomo-γ-linolenic acid, cis-
4,7,10,13,16,19-docosahexaenoic acid and a decrease in γ-
linolenic acid (Figure 4a).
Given the increased ketogenesis and reduction in triacyl-
glycerides observed in the liver for both agonists, it was
deemed important to examine how these metabolic changes
were influencing the metabolism systemically by analyzing
the blood serum of the animals.
Blood Serum
Metabolite changes unique to PPARδ activation
Amino acids increased in the PPARδ agonist treated mice
serum relative to control were aspartate and isoleucine. The
concentration of the ketone body β-hydroxybutyrate was
increased, as were the concentration of the tricarboxylic acid
(TCA) cycle metabolite fumarate and the carbohydrate
catabolite lactate. Fatty acid metabolism was also affected in
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F Fi ig gu ur re e   1 1
Clinical chemistry measurements from the serum of control, GW610742 PPARd agonist and GW347845 PPARg agonist treated ob/ob mice. ( (a a) ) Serum
insulin. ( (b b) ) Glucose. ( (c c) ) b-hydroxybutyrate. ( (d d) ) Triglyceride. ( (e e) ) Non-esterified fatty acids. ( (f f) ) HDL cholesterol. ( (g g) ) Oral glucose tolerance test. ( (h h) ) Area
under curve (AUC) oral glucose tolerance test. *P < 0.05 with respect to vehicle control treated animals. Error bars show standard error deviations
from the mean.
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(g) (h)the serum with increases in the concentration of 2-mono-
stearin, palmitelaidic acid, palmitoleic acid and tetra-
decanoic acid. The ϖ-6 essential fatty acid pathway inter-
mediate dihomo-γ-linolenic acid was also increased in
PPARδ agonist treated mice serum. UPLC-MS analysis
highlighted that the concentration of a range of triacyl-
glycerides was found to be elevated in PPARδ treated serum;
this was the reverse of the observation upon PPARγ activa-
tion, where the concentration of the same triacylglycerides
was found to be decreased (Additional file 2).
To examine the fate of the increased serum β-hydroxy-
butyrate produced by the liver through increased fatty acid
oxidation following exposure to the PPARδ agonist, the
metabolome of skeletal muscle was examined.
Skeletal muscle
Metabolite changes unique to PPARδ activation
In contrast to liver tissue amino acid metabolism, glycolysis
and the TCA cycle were profoundly affected in the skeletal
muscle of PPARδ agonist treated mice. Increases in the
concentration of aspartate and α-glycerophosphoric acid
and decreases in arginine, glutamine, glycine, methionine,
norvaline, serine, glucose, lactate and succinate were
detected (Figure 4b,c,d). Fatty acid metabolism was changed
in the skeletal muscle of PPARδ agonist treated mice, with
an increase in the -CH3, COCH2 and -(CH2)n lipid moieties
and cis-5,8,11,14,17-eicosapentaenoic acid, elaidic acid and
margaric acid. There was a concomitant decrease in palmitic
acid. The ϖ-6 essential fatty acid pathway intermediate
dihomo-γ-linolenic acid was also increased.
White adipose tissue
Given the detected systemic changes in lipid metabolism
identified in the ob/ob mice treated with the PPARδ and
PPARγ agonists, and the significant role the adipose tissue
has to play in fatty acid metabolism, analysis of fatty acid
metabolism in white adipose tissue was conducted using
GC-MS of the total fatty acid pool as well as NMR
spectroscopy of the aqueous fraction.
For both agonists no change in aqueous metabolism was
detected, indicating that the major contributions to changes
in aqueously soluble metabolites in serum where associated
with metabolic changes in other tissues.
Fatty acid metabolism in white adipose tissue from ob/ob
mice treated with the PPARδ agonist was characterized by a
decrease in the concentration of medium carbon chain fatty
acids with a concomitant increase in the concentration of the
shorter chain fatty acids. For PPARδ agonist treated white
adipose tissue an average ratio of the fatty acids
C8:0-14:0/C15:0-16:0 = 0.58, whereas for control animals
the ratio = 0.53 (P < 0.05).
Fatty acid metabolism in white adipose tissue from PPARγ
agonist treated ob/ob mice was distinguished by increased
concentration of long carbon chain fatty acids and an
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F Fi ig gu ur re e   2 2
Multivariate analysis of selected GC-MS analysis of key metabolic changes
in liver, skeletal muscle and adipose tissue. ( (a a) ) PLS-DA scores plot
showing the clustering of GC-MS chromatograms from the organic
fraction of the liver from mice treated with either a PPARd or a PPARg
agonist compared with the control group. Circle, PPARd agonist treated;
diamond, PPARg agonist treated; square, control (R2 = 0.59, Q2 = 0.82).
( (b b) ) PLS-DA scores plot showing the clustering of GC-MS chromatograms
from the aqueous phase of skeletal muscle extracts from mice treated
with either a PPARd agonist or a PPARg agonist compared with control
animals. Circle, PPARd agonist treated; diamond, PPARg agonist treated;
square, control (R2 = 0.24, Q2 = 0.32). ( (c c) ) PLS-DA scores plot showing
clustering of GC-MS chromatograms from the organic fraction of white
adipose tissue from PPARd agonist and PPARg agonist treated mice
following GC-MS analysis. Circle, PPARd agonist treated; diamond, PPARg
agonist treated; square, control (R2 = 0.58, Q2 = 0.50).
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Controlincrease in the monounsaturated fatty acid products of the
∆-9 desaturase. The ratio of C14:1-16:1 control/C14:1-16:1
PPARγ agonist = 0.87. Analysis by t-test demonstrated that
the difference between the concentration of fatty acids
C14:1-16:1 from control animals and PPARγ agonist treated
animals was statistically significant (P < 0.005).
D Di is sc cu us ss si io on n
A range of complementary metabolic profiling approaches
were used to study key tissues involved in type 2 diabetes
from ob/ob mice treated with a PPARδ or a PPARγ agonist to
understand the role of PPAR-δ in regulating systemic
metabolism. In particular we investigated the core compo-
nents of the Cori cycle to understand the implications
altered liver metabolism has on muscle tissue. While
similarities were present between the two agonists, and in
particular activation of both PPARδ and PPARγ resulted in
an increase in the insulin sensitivity and glucose tolerance of
the  ob/ob mice, PPARδ induced a number of unique
responses, particularly in liver and skeletal muscle. These
findings are consistent with the high level of PPARδ protein
expression in these tissues [23]. A decrease was detected in
glucose and galactose in all tissues, and fructose in serum
and liver from PPARδ agonist treated mice; the decrease in
glucose in serum was confirmed by clinical chemistry.
Concomitantly, an increase in lactate was detected in the
liver and serum of the treated mice, indicating a decrease in
hepatic glucose production that has previously been
observed following PPARδ activation [18]. It has been
suggested that PPARδ activation increases glyceraldehyde-3-
phosphate, formed from the 5-carbon sugar phosphates
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F Fi ig gu ur re e   3 3
Multivariate analysis of the changes in intact lipid metabolism induced by stimulation of PPARd and PPARg. ( (a a) ) PLS-DA scores plot showing the clustering
of the UPLC-MS chromatograms from the organic fraction of liver tissue from mice treated with a PPARd agonist compared with control mice. Circle,
PPARd agonist treated; square, control (R2 = 0.88, Q2 = 0.57) ( (b b) ) PLS-DA scores plot showing the clustering of the UPLC-MS chromatograms from the
organic fraction of liver tissue from mice treated with a PPARg agonist compared with control mice. Diamond, PPARg agonist treated; square, control
(R2 = 1.00, Q2 = 0.85). ( (c c) ) PLS-DA scores plot showing the clustering of the UPLC-MS chromatograms from the organic fraction of serum from mice
treated with a PPARd agonist compared with control mice. Circle, PPARd agonist treated; square, control (R2 = 0.95, Q2 = 0.82). ( (d d) ) PLS-DA scores plot
showing the clustering of the UPLC-MS chromatograms from the organic fraction of serum from mice treated with a PPARg agonist compared with
control mice. Diamond, PPARg agonist treated; square, control (R2 = 0.99, Q2 = 0.86).
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Multivariate analysis of some of the key metabolic changes induced by PPARd stimulation. ( (a a) ) PLS-DA scores plot showing the clustering of the GC-MS
chromatograms from the organic fraction of liver tissue from mice treated with a PPARd agonist compared with control mice. Circle, PPARd agonist
treated; square, control (R2 = 0.43, Q2 = 0.82). ( (b b) ) PLS-DA scores plot showing the clustering of the GC-MS chromatograms from the aqueous extracts
from skeletal muscle from mice treated with a PPARd agonist compared with control mice. Circle, PPARd agonist treated; square, control (R2 = 0.69, Q2
= 0.73). ( (c c) ) Comparison of the region of typical GC-MS chromatograms of control skeletal muscle tissue (black) and skeletal muscle tissue from mice
treated with a PPARd agonist (gray) containing the serine peak. ( (d d) ) Bar graph demonstrating the difference in the average integrated area of the serine
peak from control and PPARd agonist treated liver. Error bars show standard error deviations from the mean. *P < 0.05 with respect to vehicle control
animals.
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Controlduring the pentose phosphate shunt, which can then enter
glycolysis [18], explaining the observed reduction of glucose,
galactose and fructose in the serum and skeletal muscle.
During prolonged β-oxidation of fatty acids in the liver, the
production of acetyl-CoA can exceed the capacity of the TCA
cycle. The excess acetyl-CoA is converted to β-hydroxybuty-
rate through ketogenesis in liver mitochondria. The increased
liver and blood serum concentrations of β-hydroxybutyrate
indicate the PPARδ agonist stimulates ketone body
formation for the peripheral tissue, a change that is also
observed by clinical chemistry assays. In addition, acetic
acid was increased in the treated livers, whilst a decrease in
concentrations of non-esterified fatty acids in the serum of
PPARδ was indicative of increased tissue oxidative break-
down of fatty acids. The concentration of serum triglycerides
was increased in PPARδ agonist treated mice, as they are
mobilized for catabolism in liver and muscle. Furthermore,
increased fatty acid β-oxidation was apparent in white
adipose tissue where there were increased short and
medium chain length fatty acids in the PPARδ treated group.
These observations are consistent with previous studies
showing activation of PPARδ increases fatty acid β-oxidation
[24]. Furthermore, activation of PPARγ led to the reverse
effect with a decrease in serum triglycerides, consistent with
this receptor being involved in regulating white adipose
tissue storage of triglycerides and adipocyte expandability
[25]. The glucogenic amino acids (those that are precursors
of glucose in gluconeogenesis), glycine, glutamate, glutamine,
alanine, proline and valine, and the amino acids that are
glucogenic and ketogenic, threonine, tyrosine and phenyl-
alanine, were increased in the PPARδ agonist treated livers.
In contrast, the concentration of the ketogenic amino acid
(those that are broken down to acetyl-CoA and converted to
ketone bodies) lysine was decreased (Figure 5a). These
changes within the livers of PPARδ agonist treated mice
indicate a decrease in gluconeogenesis and an increase in
fatty acid oxidation and ketogenesis.
PPARδ agonist treated liver contained decreased linoleate
and increased linoleate pathway intermediates, γ-linolenate
and dihomo-γ-linolenate, and the pathway end product
arachidonate (Figure 5b). The ∆ 6-desaturase introduces the
initial double bond to linoleate, forming γ-linolenate. The
∆ 6-desaturase gene contains a peroxisome proliferator
response element and is known to be under PPARα
transcriptional control [26]. From this study the desaturase
also appears to be under PPARδ transcriptional control;
whilst it is worth considering that all pharmacological
agonists are likely to exhibit some ‘off target’ effects, this
study has taken into account the high affinity, specificity and
extensive characterization of GW610742 for PPARδ, even
over the highly related PPARα, which make the compound a
very selective tool for the activation of the PPARδ nuclear
receptor [27]. Van der Veen et al. demonstrated that a dose
of 20 mg/kg/day of GW610742 in mice gave an average
plasma concentration of 1 µM; given that the specificity of
GW610742 for PPARδ is 28 nM compared to 8,900 nM for
PPARα and >10,000 nM for PPARγ, then the current study
will saturate the PPARδ receptor whilst only minimally
activating the other PPAR isotypes [27]. Within the skeletal
muscle, linoleate was also decreased and dihomo-γ-linole-
nate increased but arachidonate was decreased. However,
increased arachidonic acid metabolism is not necessarily a
contradictory result when PPARδ is activated. The exact
balance between the concentrations of these pathways
presumably arises from the balance between increased β-
oxidation and the actual activity of the synthetic pathway
across the different tissues, as well as potential cross-talk
between the three different PPARs. Thus, while synthesis of
polyunsaturated fatty acids may be increased by PPARδ
stimulation, increased β-oxidation will also deplete inter-
mediates, and a new steady state will be achieved.
The  α-linolenic acid essential fatty acid pathway was also
altered in the liver of PPARδ agonist treated mice
(Figure 5c). There was a decrease in the initial metabolite in
the pathway, α-linolenic acid and a concurrent increase in
the pathways product 4,7,10,13,16,19-docosahexaenoic acid.
Two steps in the pathway are again catalyzed by the ∆ 6-
desaturase. Also, the final step in the pathway, the formation
of 4,7,10,13,16,19-docosahexaenoic acid from 6,9,12,15,18,21-
24:6, occurs via β-oxidation, which is upregulated in the
livers of PPARδ treated mice. Nevertheless, as the inter-
mediates in the pathway were not detected, the exact target
of PPARδ cannot be identified unambiguously from these
data.
PPARδ mRNA is expressed in skeletal muscle at 10-fold
higher levels than PPARα mRNA and 50-fold higher levels
than PPARγ mRNA [11]. The receptor is preferentially found
in oxidative rather than glycolytic myofibers [11]. A major
metabolic change exhibited by the PPARδ treated skeletal
muscle was a decrease in the concentration of the majority of
the observed amino acids (Figure 5d). Since skeletal muscle
lacks glucose-6-phosphatase, the amino acids will not have
been used as substrates in gluconeogenesis. An alternative
fate for the amino acids is as substrates for the TCA cycle,
which was also affected. The increased demand for TCA
cycle substrates was also apparent from the decrease in
succinate and concomitant increase in fumarate and malate.
Succinate is the substrate for complex II of the electron-
transport chain, which catalyses the formation of fumarate
and reduces coenzyme Q. PPARδ activation increases
mitochondrial biogenesis, expression of electron transport
chain components, such as cytochrome c, cytochrome c
oxidase and complex II, and induces muscle fiber type
switching to type I fibers [12]. Within the treated skeletal
muscle the concentrations of adenine were decreased and
those of adenosines and ribose sugars from the adenosines
were increased. Therefore, the decrease in amino acids may
relate to increased oxidative metabolism occurring in this
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Overview of the key metabolic changes induced by PPARd stimulation. ( (a a) ) Metabolic pathways altered in PPARd agonist treated mice liver. Metabolites
increased relative to control tissue are in red; metabolites decreased relative to control tissue are in blue. ( (b b) ) Linoleate pathway altered in PPARd agonist
treated mice liver. Metabolites increased relative to control tissue are in red; metabolites decreased relative to control tissue are in blue. ( (c c) ) Linolenate
pathway altered in PPARd agonist treated mice liver. Metabolites increased relative to control tissue are in red; metabolites decreased relative to control
tissue are in blue. ( (d d) ) Metabolic pathways altered in PPARd agonist treated mice skeletal muscle. Metabolites increased relative to control tissue are in
red; metabolites decreased relative to control tissue are in blue.
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(d)tissue. In addition, we detected an increase in the concen-
tration of creatine and phosphocreatine in muscle tissue,
which reflects the high energy phosphate buffering capacity
of the cell in addition to the increase in ATP also detected.
These changes are accompanied by a decrease in lactate
concentration and increased β-oxidation, indicating a reduc-
tion in glycolysis and a switch to more oxidative metabolism.
PPARδ activation has been implicated as a cause of skeletal
muscle atrophy [17]. As demand for amino acids increases,
one mechanism indicated by our results is that proteins are
broken down to supply substrates for the TCA cycle.
PPARδ activation also reduced the degree of saturation of
fatty acids in the skeletal muscle of the treated ob/ob mice.
Palmitate and stearate concentrations were found to be
decreased and concentrations of their monounsaturated
forms, palmitoleate and oleate, were increased. The enzyme
catalyzing these reactions, stearoyl-CoA desaturase, is under
PPAR expressional control [28].
Activation of PPARδ further improved the dyslipidemic state
in the ob/ob mice by increasing the serum HDL cholesterol
concentrations. Activation of PPARδ increases the expres-
sion of the cholesterol efflux pump ATP-binding cassette
transporter1, promoting the efflux of cholesterol from
peripheral tissues, which may lead to the observed increase
in HDL cholesterol [9].
The alterations in fatty acid metabolism detected in the white
adipose tissue of PPARδ and PPARγ agonist treated mice
were markedly different. PPARγ activation resulted in an
increase in the concentration of longer chain fatty acids,
which was indicative of fatty acid synthesis and elongation.
However, PPARδ activation in white adipose tissue decreased
the concentration of the longer chain fatty acids and
simultaneously increased the concentration of the shorter
chain fatty acids, indicative of an increase in fatty acid β-
oxidation resulting from PPARδ activation. This suggests a
mechanism by which PPARγ activation in white adipose
tissue may increase the tissue’s ability to sequester fatty acid
in a safe repository. PPARδ activation in the same peripheral
tissue appears to upregulate β-oxidation and may, therefore,
suggesting the mechanism by which activation of the nuclear
receptor increases the clearance of circulating free fatty acids
is increased β-oxidation as detected in this present study.
C Co on nc cl lu us si io on ns s
A global summary of the observed changes leads to the con-
clusion that PPARδ activation generates a systemic change
in energy balance in which the Cori cycle is profoundly
affected. A decrease in hepatic glucose production produces
an increase in hepatic and circulating lactate concentrations
and a drop in circulating blood glucose; under these
conditions, hepatic metabolism begins to favor fatty acid β-
oxidation and ketogenesis, with ketone bodies released into
circulation to maintain energy supply to peripheral tissues.
Furthermore, glucose is decreased within skeletal muscle
alongside increased TCA cycle intermediates but without an
observed increase in lactate, correlating with the observed
increase in oxidative metabolism. Therefore, the activation
of PPARδ produces a marked switch from the Cori cycle to
ketone and fatty acid metabolism between the liver and
oxidative skeletal muscle, which may contribute to the
observed improvement in insulin sensitivity.
In conclusion, to understand the global physiological and
pharmacological effects of PPARδ activation, which may give
rise to further applications for PPARδ agonists, compound
treatment studies have been performed on an ob/ob mouse
background. The combined metabolomic study of liver,
skeletal muscle and serum identified multiple changes in
metabolism in the PPARδ agonist treated mice. These
changes showed that PPARδ activation profoundly affected
glycolysis, gluconeogenesis, the TCA cycle and linoleic acid
and α-linolenic acid essential fatty acid pathways; many of
the changes were found to correlate well with known PPAR
controlled gene expression. While some of these metabolic
perturbations could be induced by a selective PPARγ agonist,
there were also specific changes associated with PPARδ,
demonstrating the complexity of the PPAR system and
cross-talk between different receptors when considering
systemic metabolism.
A Ab bb br re ev vi ia at ti io on ns s
GC, gas chromatography; HDL, high-density lipoprotein;
MS, mass spectrometry; MS/MS, tandem mass spectro-
metry; NMR, nuclear magnetic resonance; PCA, principal
components analysis; PLS-DA, partial least squares-discri-
minate analysis; PPAR, peroxisome proliferator-activated
receptor; TCA, tricarboxylic acid; TSP, sodium-3-
(trimethylsilyl)-2,2,3,3-tetradeuteriopropionate; UPLC,
ultra performance liquid chromatography, VIP, Variable
Importance Parameter.
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